ANZCTR - Registration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12619000898156

Ethics application status

Approved

Date submitted

5/06/2019

Date registered

26/06/2019

Date last updated

12/10/2022

Date data sharing statement initially provided

26/06/2019

Date results information initially provided

22/10/2021

Type of registration

Retrospectively registered

Titles & IDs

Public title

Follow-on study of a multicentre randomised, controlled trial (PPOIT-003) evaluating the long-term safety and efficacy of Probiotic and Peanut Oral Immunotherapy (PPOIT) compared with Oral Immunotherapy (OIT) alone and with placebo in peanut allergic individuals

Scientific title

Secondary ID [1]

NIL

Universal Trial Number (UTN)

Trial acronym

PPOIT-003LT

Linked study record

This record is a follow-up study of ACTRN12616000322437 (A multicentre, randomized, controlled trial evaluating the effectiveness of Probiotic and Peanut Oral Immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with Oral Immunotherapy (OIT) alone and with placebo)

Health condition

Health condition(s) or problem(s) studied:

Peanut Allergy

Food Allergy

Condition category

Condition code

Inflammatory and Immune System

Allergies

Intervention/exposure

Study type

Observational

Patient registry

False

Target follow-up duration

Target follow-up type

Description of intervention(s) / exposure

This is a multicentre follow-on study of the PPOIT-003 study (ACTRN12616000322437). There is no treatment intervention in this study.

Although it is a follow -on study, PPOIT-003LT has been approved under a separate ethics submission.

All participants who complete the PPOIT-003 will be eligible for enrolment into this follow-on study.

Subjects and study staff will remain blinded to their PPOIT-003 treatment allocation and will continue with peanut avoidance or ingestion according to the instructions they received at the end of treatment in PPOIT-003 (based upon their treatment outcome at end of treatment in PPOIT-003).

F0 (First visit):
- The following assessments will be conducted: skin prick test, medical history review, blood and stool collection, Food Allergy Quality of Life questionnaire.

F1 time point (12 months after F0 or 24 months after the final day of treatment)
- phone call will be conducted for the following:
- Allergy Questionnaire
- Food Allergy Quality of Life questionnaire
- Reminder for parent/participant to continue with diary recording (either mobile app or paper).

F2 time point (24 months after F0 or 36 months after the final day of treatment)
A visit will be conducted at this time point for the following:
• Weight/height;
• Skin prick test (peanut, egg, milk, cashew, almond, pistachio, hazelnut, dust mite and positive
and negative control);
• Blood and faecal sample (faecal sample collected by parents at home);
• Anaphylaxis education;
• Allergy questionnaire;
• Food Allergy Quality of Life-Parent Form (FAQL-PF) and age appropriate Food Allergy Quality of Life forms (i.e. participants aged 8-12 years and 13-17 years to complete Food Allergy Quality of Life-Child Form (FAQLQ-CF) and Food Allergy Quality of Life-Teenager Form (FAQLQ-TF) respectively);
Please note, in unavoidable circumstances (e.g. school camps), the window for the F2 time point can be +/- 14 days to accommodate parent/participant availability. Where a face-to-face visit is not possible, the visit will be conducted by phone and SPT, bloods and stool test will not be performed.

F3 time point (36 months after F0 or 48 months after the final day of treatment)
A visit will be conducted at this time point for the following:
• Weight/height;
• Skin prick test (peanut, egg, milk, cashew, almond, pistachio, hazelnut, dust mite and positive
and negative control);
• Blood and faecal sample (faecal sample collected by parents at home);
• Anaphylaxis education;
• Allergy questionnaire;
• Food Allergy Quality of Life-Parent Form (FAQL-PF) and age appropriate Food Allergy Quality of Life forms (i.e. participants aged 8-12 years and 13-17 years to complete Food Allergy Quality of Life-Child Form (FAQLQ-CF) and Food Allergy Quality of Life-Teenager Form (FAQLQ-TF) respectively);
• Medical history as clinically indicated prior to DBPCFC or OFC;
• Double blind, placebo controlled food challenge (DBPCFC) or open OFC** for subjects with Sustained Unresponsiveness (SU) and Desensitisation (DS) without SU;
• Double blind, placebo controlled food challenge (DBPCFC) or open OFC** for subjects with
allergy if SPT <8mm and no recent immediate objective allergic reaction to peanut in the last
6 months;
• Spirometry as clinically indicated before each DBPCFC or OFC (all children over 8 years)
A 2nd DBPCFC or OFC will be performed for DS without SU subjects if they pass the 1st F3 DBPCFC or OFC. These subjects will commence an 8-week period of peanut elimination after passing the first F3 DBPCFC or OFC, after which they will undergo a 2nd DBPCFC or OFC to assess for conversion to SU. The 2nd DBPCFC or OFC must be a minimum of 8 weeks post the 1st F3 challenge part A.
If the 1st DBPCFC or OFC is conducted more than 3 months after the F3 visit (for those who had the F3 visit prior to the protocol amendment (version 5), a repeat skin prick test and blood collection will be performed for the subject.
**The decision for DBPCFC or open OFC is at the discretion of the site investigator
The window for the F3 timepoint DBPCFC or OFC can be +/- 6 months (from 3.5 to 4.5 years post-treatment) to accommodate parent/participant availability.
Where a face-to-face visit is not possible, the visit will be conducted by phone and SPT, bloods and stool test will not be performed.

F4 time point (48 months after F0 or 60 months after the final day of treatment)
A visit will be conducted at this time point for the following:
• Weight/height;
• Skin prick test (peanut, egg, milk, cashew, almond, pistachio, hazelnut, dust mite and positive
and negative control);
• Blood and faecal sample (faecal sample collected by parents at home);
• Anaphylaxis education;
• Allergy questionnaire;
• Food Allergy Quality of Life-Parent Form (FAQL-PF) and age appropriate Food Allergy Quality of Life forms (i.e. participants aged 8-12 years and 13-17 years to complete Food Allergy Quality of Life-Child Form (FAQLQ-CF) and Food Allergy Quality of Life-Teenager Form (FAQLQ-TF) respectively);
Please note, in unavoidable circumstances (e.g. school camps), the window for the F4 time point can be +/- 14 days to accommodate parent/participant availability. Where a face-to-face visit is not possible, the visit will be conducted by phone and SPT, bloods and stool test will not be performed.

F5 time point (60 months after F0 or 72 months after the final day of treatment)
A visit will be conducted at this time point for the following:
• Weight/height;
• Skin prick test (peanut, egg, milk, cashew, almond, pistachio, hazelnut, dust mite and positive and negative control);
• Blood and faecal sample (faecal sample collected by parents at home);
• Anaphylaxis education;
• Allergy questionnaire;
• Food Allergy Quality of Life-Parent Form (FAQL-PF) and age appropriate Food Allergy Quality of Life forms (i.e. participants aged 8-12 years and 13-17 years to complete Food Allergy Quality of Life-Child Form (FAQLQ-CF) and Food Allergy Quality of Life-Teenager Form (FAQLQ-TF) respectively);
Note: in unavoidable circumstances (e.g. school camps), the window for the F5 time point can be +/- 14 days to accommodate parent/participant availability. Where a face-to-face visit is not possible, the visit will be conducted by phone and SPT, bloods
and stool test will not be performed.

- This is the end point of the follow on study and participants will return to their Clinical Allergist for ongoing clinical care.

Intervention code [1]

Not applicable

Comparator / control treatment

Active control (peanut avoidance) with no treatment given,

Control group

Active

Outcomes

Primary outcome [1]

Proportion of subjects who are ingesting peanut in their diet and number and severity of reactions to peanut ingestion (intentional or accidental) during the follow-on study phase in PPOIT, OIT and placebo groups as well as in subjects with Sustained Unresponsiveness (SU) vs Desensitisation (DS) without SU vs allergic status.
This will be assessed using allergy questionnaires, quality of life forms and a study diary (in the form of a mobile app or paper).

Timepoint [1]

F1 visit - 24 months post PPOIT 003 T1 visit (ACTRN12616000322437)
F2 visit - 36 months post PPOIT 003 T1 visit (ACTRN12616000322437)
F3 visit - 48 months post PPOIT 003 T1 visit (ACTRN12616000322437)
F4 visit - 60months post PPOIT 003 T1 visit (ACTRN12616000322437)
F5 visit - 72 months post PPOIT 003 T1 visit (ACTRN12616000322437)

Secondary outcome [1]

Quality of life scores and change in quality of life scores from baseline in PPOIT-003 study at
12 months (F1), 24 months (F2), 36 months (F3), 48 months (F4) and 60 months (F5) post-treatment in PPOIT, OIT and placebo groups as well as in subjects with sustained unresponsiveness (SU) vs Desensitisation (DS) without SU vs allergic status (determined at end of treatment in PPOIT-003 study). This will be assessed using quality of life forms.

Timepoint [1]

F1 visit - 12 months post PPOIT 003 T1 visit (ACTRN12616000322437) F2 visit - 24 months post PPOIT 003 T1 visit (ACTRN12616000322437) F3 visit - 36 months post PPOIT 003 T1 visit (ACTRN12616000322437) F4 visit - 48 months post PPOIT-003 T1 visit (ACTRN12616000322437) F5 visit - 60 months post PPOIT-003 T1 visit. (ACTRN12616000322437)

Secondary outcome [2]

Changes from PPOIT-003 study baseline in peanut and peanut component sIgE and sIgG4
levels and peanut skin prick test (SPT) at 36 months (F2), 48 months (F3), 60 months (F4) and
72 months (F5) post-treatment in PPOIT vs OIT vs placebo groups and in subjects with SU vs
DS without SU vs allergic status. This a composite secondary outcome. sIgE levels and sIgG4 levels will be assessed using plasma samples and measured by ImmunoCAP (Phadia).

Timepoint [2]

F2 visit - 36 months post PPOIT 003 T1 visit (ACTRN12616000322437)
F3 visit - 48 months post PPOIT 003 T1 visit (ACTRN12616000322437)
F4 visit - 60 months post PPOIT-003 T1 visit (ACTRN12616000322437)
F5 visit - 72 months post PPOIT-003 T1 visit. (ACTRN12616000322437)

Secondary outcome [3]

Measure of participants with persistent SU at 48 months (F3) post-treatment amongst subjects who achieved SU at end of treatment in PPOIT vs OIT vs placebo groups. This will be assessed by performing a food challenge at F3.

Timepoint [3]